Chequerboard and time-kill methods were used to compare the in vitro efficacies of the combinations gatifloxacin (GAT) with cefoperazone (CFP) and GAT with cefoperazonesulbactam (CFP-SUL) against 58 clinical isolates of Pseudomonas aeruginosa. The combinations GAT+CFP and GAT+CFP-SUL were shown to be synergistic for 36.2 and 58.6 % of isolates tested, respectively, using the chequerboard method. Time-kill studies with 11 strains showed synergy in 54.5 % for the GAT+CFP combination and 72.7 % for the GAT+CFP-SUL combination. The agreement between these two methods was found to be 72-81 %. There was a significant difference in synergy between the two combinations tested (P50.011).
INTRODUCTION
Resistance to antimicrobial agents has resulted in morbidity and mortality from treatment failures, and increased health-care costs. Although defining the precise publichealth risk and estimating the increase in costs is not a simple undertaking, there is little doubt that the emergent antibiotic resistance is a serious global problem.
Despite improvements in antimicrobial therapy, Pseudomonas aeruginosa remains one of the most prominent Gramnegative bacteria causing nosocomial infections, and comprises 16 % of nosocomial pneumonia cases, 12 % of hospital-acquired urinary tract infections, 8 % of surgical wound infections and 10 % of bloodstream infections (Rossolini & Mantengoli, 2005) . This organism is uniquely problematic because of a combination of inherent resistance to many drug classes and its ability to acquire resistance to all relevant treatments (Rossolini & Mantengoli, 2005) . Resistance mechanisms include low outer-membrane permeability, multidrug efflux pumps (tetracycline, imipenem, fluoroquinolones and aminoglycosides) and the production of antibiotic-modifying enzymes such as metallo-b-lactamases (aminoglycosides and b-lactams) (Rossolini & Mantengoli, 2005) . The development of vaccines and new antimicrobial agents has not kept pace with resistance; therefore, the search for other methods of therapy, such as synergistic combinations, is necessary.
Combination therapy is used with the aim of expanding the antimicrobial spectrum, minimizing toxicity, preventing the emergence of resistant mutants during therapy and obtaining synergistic antimicrobial activity (Eliopoulos & Moellering, 1991) . Many antimicrobial combinations have been studied for synergy in vitro and in vivo against P. aeruginosa (Dawis et al., 2003; Fish et al., 2002; Gradelski et al., 2001; Mayer & Nagy, 1999) . In this study, we investigated the activity of gatifloxacin (GAT), alone and in combination with cefoperazone (CFP) and cefoperazone-sulbactam (CFP-SUL) (2 : 1), against 58 clinical isolates of P. aeruginosa. . Antimicrobial solutions were prepared and freshly diluted on the day of testing. Each test was performed in duplicate (CLSI, 1999) .
Synergy testing
Chequerboard method. Chequerboard synergy testing was performed in sterile glass test tubes using the macrodilution technique. The concentration ranges and inoculum were the same as used for MIC determination. Antimicrobial solutions were prepared and freshly diluted on the day of the test. Each test was performed in duplicate. Time-kill method. From each of the above-classified susceptibility groups, three strains (except for CFP-resistant strains, where two strains were used instead of three) were tested by a time-kill method as described by Bajaksouzian et al. (1996) and Visalli et al. (1998) . Antimicrobial solutions were prepared and freshly diluted on the day of testing. All antimicrobial agents were tested alone and in combination. In each case, concentrations ranging from four times above to four times below the MIC were tested. Drug carryover was addressed as described by Bajaksouzian et al. (1996) . Each test was performed in duplicate. Viability counts were performed in duplicate at 0, 6, 12 and 24 h by plating on MH agar. Synergy was defined as a ¢2 log 10 decrease in the viable count with the combination at 24 h compared with that of the more active of each of the two compounds tested alone. Indifference was defined as a ¢2 log 10 increase or decrease in colony count at 24 h by the combination compared with that by the most active drug alone. Antagonism was defined as a ¢2 log 10 increase in colony count at 24 h by the combination compared with that by the most active drug alone (Bajaksouzian et al., 1996; Visalli et al., 1998) .
Statistical determination. Statistical significance was determined using the McNemar test.
RESULTS
In susceptibility testing, 43 % of the isolates were found to be resistant to GAT, 36 % were resistant to CFP and 25 % were resistant to CFP-SUL. Table 2 . Synergistic FIC indices for the GAT+CFP combination were found in 21/58 strains (36.2 %), which comprised 11/31 strains susceptible to all agents tested, 2/6 strains resistant to GAT alone, 2/2 strains resistant to CFP alone and 6/19 strains classified as miscellaneous. For the GAT+CFP-SUL combination, synergistic FIC indices were found in 34/58 strains (58.6 %), which included 17/31 strains susceptible to all agents tested, 4/6 strains resistant to GAT alone, 2/2 strains resistant to CFP alone and 11/19 strains classified as miscellaneous.
The results of the time-kill synergy tests are listed in Table  3 . Time-kill studies revealed synergy in 6/11 strains (54.5 %) for the GAT+CFP combination and 8/11 (72.7 %) strains for the GAT+CFP-SUL combination. In contrast, the chequerboard titrations with these strains showed synergy for three strains (27.3 %) with the GAT+CFP combination and for six strains (54.5 %) with *Susceptible to all agents tested. DResistant to all agents tested (n514) and resistant to GAT and CFP (n55). Combination therapy for resistant P. aeruginosa strains the GAT+CFP-SUL combination. Concordance of the chequerboard and time-kill testing was demonstrated in 8/11 strains for the GAT+CFP combination and 9/11 strains for the GAT+CFP-SUL combination. Synergy between GAT and CFP-SUL was significantly (P50.011) more common than that between GAT and CFP.
DISCUSSION
Multidrug-resistant P. aeruginosa is an important causative agent of nosocomial infections. b-Lactams, aminoglycosides and fluoroquinolones have been the mainstay in the treatment of P. aeruginosa infections. Combination treatments are effective choices against nosocomial infections caused by multidrug-resistant isolates (PDR, 2004) .
Combinations of fluoroquinolones with other agents have been investigated extensively (Dawis et al., 2003; Fish et al., 2002; Gradelski et al., 2001; Mayer & Nagy, 1999) . Most of the studies combining fluoroquinolones with aminoglycosides have shown indifference against members of the Enterobacteriaceae and against P. aeruginosa, whereas fluoroquinolones with anti-pseudomonal penicillins have been reported to be synergistic against 20-50 % of P. aeruginosa isolates (Neu & Chin, 1994) . Gradelski et al. (2001) reported that the in vitro effect of GAT with CFP was synergistic against 40-60 % of P. aeruginosa strains by time-kill methods. Furthermore, it was reported that amikacin in combination with GAT was synergistic against P. aeruginosa but the efficiency was least when compared with a GAT and b-lactam combination.
Two methods to detect in vitro synergy -a chequerboard and a time-kill assay -were performed for GAT+CFP and GAT+CFP-SUL combinations against 58 clinical isolates of P. aeruginosa. The combinations GAT+CFP and GAT+CFP-SUL were found to be synergistic for 36.2 and 58.6 % of the isolates tested, respectively, using the chequerboard method. The rate of synergy of GAT+CFP correlates with earlier reports using this combination (Gradelski et al., 2001 ). There was a significant difference in synergy between the two combinations (P50.011). Our study showed that GAT at sub-MIC concentrations of ,0.2520.5 mg ml 21 was synergistic at 24 h when combined with CFP-SUL in 4/11 strains and had comparatively lower synergy rates when combined with CFP alone.
Synergy testing methods are not standardized for reproducibility and interpretation, and therefore it is extremely difficult to compare the results of these methods from different studies. The chequerboard test measures only the inhibitory concentration, and in time-kill studies the concentration is fixed and does not decrease as it would in vivo. The time parameter of 24 h can limit or alter the results of an experiment if regrowth occurs with one or both antimicrobial agents (Pankey & Ashcraft, 2005) . Although each of these methods uses different conditions and end points, there is frequent agreement between the results of the two methods. In our study, the agreement between these two methods was 72-81 %. Ad, Additive or indifferent; C, chequerboard titration; Sy, synergistic; T, time-kill studies.
In conclusion, our study demonstrated synergy in the combinations GAT+CFP and GAT+CFP-SUL against clinical isolates of P. aeruginosa. Although it is interesting that we could demonstrate in vitro synergy against some P. aeruginosa isolates, the mechanism of the exhibited synergy is unknown and needs to be explored. Also, no evidence of in vivo synergy has been found. Clinical studies are necessary to test the validity of these in vitro findings, as well as the significance of regrowth after 24 h.
